MAKSCIENTIFIC

Timeline

1. May 13, 2025 Grant Government grant — SBIR: $55,000 (annual award, as published), announced May 13, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

Funding

Last 2 years.

• May 13, 2025 Government grant — SBIR: $55,000 (annual award, as published), announced May 13, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

NIH awards 15

Annual award amounts. Total $5.2M.

• Aug 26, 2024 NIH award 1R44DK139888-01 FY2024: $572,743 awarded for that fiscal year; activity R44 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. A CB1 Antagonist for Treatment of source ↗
• May 30, 2023 NIH award 1R43DA057439-01 FY2023: $320,000 awarded for that fiscal year; activity R43 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. Dual Fatty Acid Amide Hydrolase ( source ↗
• Sep 15, 2020 NIH award 1U18DA052537-01 FY2020: $218,855 awarded for that fiscal year; activity U18 (OTHER_NIH); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. Dual Fatty Acid Amide Hydrol source ↗
• Sep 13, 2019 NIH award 1R41DK115303-01A1 FY2019: $224,999 awarded for that fiscal year; activity R41 (STTR); PI MAKRIYANNIS, ALEXANDROS; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. Lead Optimization of Peripheral CB source ↗
• Aug 22, 2017 NIH award 5R44DK104636-03 FY2017: $646,219 awarded for that fiscal year; activity R44 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. NAAA Inhibitors as Anti-inflammat source ↗
• Sep 23, 2016 NIH award 2R44DK104636-02 FY2016: $646,219 awarded for that fiscal year; activity R44 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. NAAA Inhibitors as Anti-inflammat source ↗
• Apr 1, 2015 NIH award 1R43DK104636-01 FY2015: $232,633 awarded for that fiscal year; activity R43 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. NAAA Inhibitors as Anti-Inflammat source ↗
• May 30, 2014 NIH award 1R43DA036982-01A1 FY2014: $221,844 awarded for that fiscal year; activity R43 (SBIR); PI ALAPAFUJA, SHAKIRU OLAJIRE; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. Cannabinergic Receptor Antagoni source ↗
• Jan 6, 2011 NIH award 5R44DA023737-03 FY2011: $516,628 awarded for that fiscal year; activity R44 (SBIR); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. New Drugs to Enhance Endocannabinoid Responses source ↗
• 2010 NIH contract (government contract; not a grant and not an investment round) 271200900031C-2-0-1 FY2010: $23,826 awarded for that fiscal year; activity N44 (OTHER_NIH); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. NOVEL AZETIDINE C source ↗
• Aug 3, 2009 NIH award 2R44DA023737-02 FY2009: $489,260 awarded for that fiscal year; activity R44 (SBIR); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. New Drugs to Enhance Endocannabinoid Responses source ↗
• 2009 NIH contract (government contract; not a grant and not an investment round) 271200900031C-1-0-1 FY2009: $726,174 awarded for that fiscal year; activity N44 (OTHER_NIH); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. NOVEL AZETIDINE source ↗
• 2008 NIH contract (government contract; not a grant and not an investment round) 271200800010C-2-0-1 FY2008: $119,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI n/a; recipient as written: MAKSCIENTIFIC, LLC, BURLINGTON, MA. Novel Azetidine CB1 Antag source ↗
• Aug 27, 2007 NIH award 1R43DA023737-01 FY2007: $130,066 awarded for that fiscal year; activity R43 (SBIR); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, Watertown, MA. New Drugs to Enhance Endocannabinoid Responses f source ↗
• Sep 29, 2004 NIH award 1R43DA018031-01 FY2004: $154,017 awarded for that fiscal year; activity R43 (SBIR); PI GOLIK, JERZY; recipient as written: MAKSCIENTIFIC, LLC, Watertown, MA. CB1 Receptor Antagonists in Drug Abuse source ↗